Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.

While not co-developing each other’s drugs, J&J and financially troubled RallyBio are working on complementary approaches to the rare disease fetal and neonatal alloimmune thrombocytopenia.

A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.

CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.